Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pegasys Induction and High-Dose Copegus in HCV Genotype 1
NCT00394277Phase 4Completed
- Sponsor
- Roche
- Start
- Feb 2007
- Primary completion
- Apr 2009
- Modality
- Orthosteric Ligands, Cytokines & Interferons, Metabolically Activated Prodrugs
- Countries
- 15
01
Overview
Phase 4, randomised, double-blind trial of pegylated interferon alpha and ribavirin in hepatitis C (HCV) (4 arms), sponsored by Roche. Primary endpoint: Sustained Virological Response at 24 weeks post-treatment. Started Feb 2007; status: completed.
02
Drugs
pegylated interferon alpharibavirin
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT00394277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00394277.